Shingles Vaccines Market Report
First published: 10 October 2024 | Last updated: 28 May 2026 | Report Code: shingles-vaccines
Shingles Vaccines Market — USD 3.5 billion in 2023, Growing to USD 7.37B by 2033 at 7.5% CAGR
This report provides an in-depth analysis of the Shingles Vaccines market, focusing on market size, growth potential, and trends from 2023 to 2033. Key segments, regional insights, and forecasts are included to offer a comprehensive view of this evolving industry.
Key Takeaways
- Global market projected to expand from $3.50 Billion in 2023 to $7.37 Billion by 2033 at a 7.5% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe increases from $1.06 Billion in 2023 to $2.24 Billion in 2033, reflecting robust adoption in that region.
- Asia Pacific rises from $0.67 Billion in 2023 to $1.42 Billion in 2033, indicating expanding access and awareness.
- Major suppliers include Merck & Co., Inc., GlaxoSmithKline (GSK), Sanofi Pasteur, and Pfizer Inc., central to vaccine availability and innovation.
Shingles Vaccines Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This report presents a structured view of the Shingles Vaccines market across product types, administration routes, age groups, distribution channels, and end users. Market size is $3.50 Billion in 2023 and is forecast to reach $7.37 Billion by 2033 at a 7.5% CAGR for 2023 to 2033. Key growth drivers include demographic aging, heightened vaccination awareness, and technological improvements in vaccine design and delivery. The analysis highlights regional performance with North America as the largest market and detailed figures for Europe, Asia Pacific, Latin America, and Middle East and Africa. Segmentation covers live and recombinant vaccines, intradermal and subcutaneous administration, end users such as hospitals, pharmacies, and clinics, and distribution channels including direct sales, online sales, and retail pharmacies. Competitive coverage profiles leading firms such as Merck & Co., Inc., GlaxoSmithKline (GSK), Sanofi Pasteur, and Pfizer Inc., and discusses strategic initiatives influencing market positioning.
Key Growth Drivers
- Aging populations increase demand for shingles prevention among older adults, raising vaccine uptake.
- Greater public awareness and vaccination campaigns drive higher immunization rates and market expansion.
- Advances in vaccine technology and formulations improve effectiveness, supporting broader adoption.
- Expanded distribution channels, including online and retail pharmacies, increase accessibility for end users.
- Sustained investment by leading companies strengthens product availability and supports market development.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $3.50 Billion |
| CAGR (2023-2033) | 7.5% |
| 2033 Market Size | $7.37 Billion |
| Top Companies | Merck & Co., Inc., GlaxoSmithKline (GSK), Sanofi Pasteur, Pfizer Inc. |
| Published Date | 10 October 2024 |
| Last Modified Date | 28 May 2026 |
Shingles Vaccines Market Overview
Customize Shingles Vaccines Market Report market research report
- ✔ Get in-depth analysis of Shingles Vaccines market size, growth, and forecasts.
- ✔ Understand Shingles Vaccines's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Shingles Vaccines
What is the Market Size & CAGR of Shingles Vaccines Market Report market in 2023?
Shingles Vaccines Industry Analysis
Shingles Vaccines Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Shingles Vaccines Market Report Market Analysis Report by Region
Europe Shingles Vaccines Market Report:
Europe grows from $1.06 Billion in 2023 to $2.24 Billion in 2033. Growth is supported by public vaccination programs, heightened awareness among older populations, and investment in preventive healthcare services across the region.Asia Pacific Shingles Vaccines Market Report:
Asia Pacific grows from $0.67 Billion in 2023 to $1.42 Billion in 2033. Increased access, rising awareness of shingles risks in older age groups, and expanding distribution channels contribute to the region’s upward movement.North America Shingles Vaccines Market Report:
North America is largest regional market, rising from $1.21 Billion in 2023 to $2.54 Billion in 2033. This trajectory reflects established immunization infrastructure, strong uptake among older adults, and extensive availability through hospitals, pharmacies, and clinics.South America Shingles Vaccines Market Report:
Latin America grows from $0.13 Billion in 2023 to $0.26 Billion in 2033. Expansion is linked to improving vaccine availability, targeted immunization initiatives, and growing attention to adult preventive care in select markets.Middle East & Africa Shingles Vaccines Market Report:
Middle East and Africa grows from $0.43 Billion in 2023 to $0.91 Billion in 2033. Growth factors include gradual expansion of immunization programs, rising awareness among older adults, and improved delivery networks across countries.Tell us your focus area and get a customized research report.
Research Methodology
Shingles Vaccines Market Analysis By Product
Total market for live vaccines is expected to reach $6.42 billion by 2033, maintaining an 87.17% share across the years, while recombinant vaccines are projected to increase from $0.45 billion to $0.95 billion by 2033, representing a smaller yet significant portion.
Shingles Vaccines Market Analysis By Administration Route
IIntradermal routes accounted for $3.05 billion in 2023 and are projected to rise to $6.42 billion by 2033, while subcutaneous routes, currently $0.45 billion, are expected to reach $0.95 billion.
Shingles Vaccines Market Analysis By Age Group
The market for individuals aged 50 years and older is expected to reach $6.42 billion by 2033, while the market for those under 50 years is anticipated to grow from $0.45 billion to $0.95 billion.
Shingles Vaccines Market Analysis By End User
Hospitals remain the primary end-user segment, growing from $2.27 billion in 2023 to $4.77 billion by 2033, while pharmacies and clinics also contribute to increasing market sizes of $1.57 billion and $1.03 billion respectively.
Shingles Vaccines Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Shingles Vaccines Industry
Merck & Co., Inc.:
Merck is a leading player in the Shingles Vaccines market, known for its Zostavax and Shingrix vaccines, which address the rising need for shingles prevention.GlaxoSmithKline (GSK):
GSK manufactures Shingrix, a highly effective vaccine that has contributed significantly to the market's growth and is recognized for its efficacy in preventing shingles.Sanofi Pasteur:
Sanofi Pasteur is involved in developing vaccines aimed at providing immunization against herpes zoster and is expanding its presence in several regions.Pfizer Inc.:
Pfizer is actively engaged in research for innovative vaccine solutions including those for shingles, contributing to the overall market development.We're grateful to work with incredible clients.
FAQs
What is the current market size?
The market size for 2023 is $3.50 Billion according to the report, reflecting the baseline value used for forecasting through the 2023 to 2033 period.
How big will the market be in 2033?
The market is projected to reach $7.37 Billion by 2033, using the report’s forecast horizon of 2023 to 2033 and reflecting anticipated demand growth.
What is CAGR?
The Compound Annual Growth Rate (CAGR) for the forecast period 2023 to 2033 is 7.5%, which defines the average annual growth rate used in the report’s projections.
Is there a single fastest Growing region in the Shingles Vaccines Market Report market?
No single fastest-growing region is stated for the Shingles Vaccines Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Why is North America the largest region?
North America’s scale reflects higher baseline uptake and infrastructure for adult immunization as indicated by the region’s increase from $1.21 Billion in 2023 to $2.54 Billion in 2033.
Who are the top companies?
Top companies listed in the report include Merck & Co., Inc., GlaxoSmithKline (GSK), Sanofi Pasteur, and Pfizer Inc., which influence market supply and innovation.
What drives regional growth?
Regional growth is driven by demographic trends, vaccination awareness, regulatory support, and improvements in distribution networks, as discussed alongside the provided regional figures.
How is the market segmented?
The market is segmented by product (live and recombinant vaccines), administration route (intradermal, subcutaneous), age group, end user, and distribution channel, per the report’s structure.